50 results about "Lungs metastasis" patented technology

The invention relates to the technical field of tumor marker detection, in particular to a breast cancer lung metastasis related biomarker screening system which comprises a differential genetic factor mining module, a function association module, a verification screening module, an interference elimination module and an optimization integration module. According to the method, the candidate genetic factors highly associated with lung metastasis are extracted, and the expression fluctuation characteristics are combined to carry out difference analysis, so that the preliminary screening accuracy is improved, pathological information and pathway annotation are integrated to construct an action network, pathway weights are analyzed, and functional expressions of the candidate factors are quantitatively evaluated; an independent sample is called to verify transcription consistency and clinical relevance, interference factors with poor repeatability are eliminated, non-tumor tissue high-expression interference items are rejected in combination with background transcription characteristics, the specificity and adaptability of screening results are improved, and finally a marker set with metastasis mechanism indicating significance and prognosis prediction value is formed through comprehensive evaluation. And clinical transformation support is provided for identification of lung metastasis of breast cancer.

This invention relates to the application of β-sitosterol glycoside in the preparation of products for treating lung cancer. This invention creatively provides a new use for the active monomer β-sitosterol glycoside, demonstrating that β-sitosterol glycoside can significantly inhibit the migration ability of lung cancer cells at doses without cell proliferation inhibitors, clarifying the specificity of its anti-metastatic effect, and laying the foundation for further new drug development of this monomer component. Through an in vivo mouse lung metastasis model, this invention demonstrates that β-sitosterol glycoside effectively inhibits the formation of lung metastases while exhibiting no significant toxic side effects in experimental animals, demonstrating high safety, and providing a new candidate molecule for the development of low-toxicity, highly effective anti-lung cancer metastasis drugs.

The application belongs to the technical field of nanomedicine, tumor treatment and immunotherapy, and specifically provides a copper death selective induction nanoparticle targeting tumor mitochondria, which is prepared by the following preparation method: S1, TPY is specifically coupled with MHI through a condensation reaction to obtain MTPY; S2, MTPY is complexed with copper ions to obtain an MTPY-Cu complex; and S3, the MTPY-Cu complex is self-assembled with albumin to form an MTPY-Cu@Alb nanoparticle. The copper dose of the application is only 1 / 1000 of that of free Cu 2+ , and the equivalent immune regulation and killing effects can be achieved; the primary tumor and distant tumor foci can be inhibited, and lung metastasis can be reduced; and the application can induce immune memory and prevent recurrence; the application is combined with cisplatin to significantly enhance the therapeutic effect and reverse the induced immunosuppression; and the application has high biological safety, and has no obvious hepatorenal toxicity or hemolytic reaction.

The invention discloses a mouse liver cancer cell line with a high lung metastasis characteristic as well as a construction method and application thereof, and belongs to the technical field of biology and oncology. The cell is preserved in China Center for Type Culture Collection on February 4, 2026, the preservation address is Wuhan University, Wuhan, China, and the preservation number is CCTCC NO: C202621. The PNV-LM3 cell line provided by the invention is constructed by combining a PTEN KO and NRAS G12V mutated hydrodynamic tail vein injection model with tail vein injection in-vivo domestication, a mouse liver cancer model is successfully induced to generate lung metastasis, and the lung metastasis tendency of the cell line is greatly enhanced. Compared with a traditional Hepa1-6 cell line, the PNV-LM3 cell line has the advantages that the lung metastasis process of the liver cancer is more accurately and efficiently reproduced, and a more real experimental platform is provided for research of a liver cancer metastasis mechanism.

The application provides a combined drug, a liposome, a biomimetic liposome, a preparation method of the combined drug, the liposome and the biomimetic liposome, and application of the combined drug, the liposome and the biomimetic liposome in preparation of an anti-breast cancer lung metastasis drug, and belongs to the technical field of biological medicines. The combined drug comprises panatinib and ginsenoside Rg3. The application further provides a liposome PNT-Rg3-Lipo for simultaneously loading the two, and a biomimetic liposome MM / PNT-Rg3-Lipo coated with a macrophage membrane. Experiments show that the combination of the two can synergistically regulate chemokines CXCL1 , CXCL2 and CXCL11 , and the effect is better than the sum of the single use. The MM / PNT-Rg3-Lipo has uniform particle size, retains integrin alpha 4 / beta 1 functional proteins, can target lung metastases, significantly reduces metastatic nodules, and has good biocompatibility. The application provides an effective new strategy for resisting breast cancer lung metastasis.

The application belongs to the technical field of biological medicine, and particularly relates to a nucleic acid aptamer targeting MOTS-c and application thereof. The target sequence of the aptamer is SEQ ID NO:1, and the sequence of the nucleic acid aptamer is SEQ ID NO:2. The aptamer has good affinity with MOTS-c, can significantly inhibit the stemness characteristics of cancer cells by treating the cancer cells, significantly improve the lung metastasis of tumor-bearing mice, has good blocking effect on MOTS-c in vivo and in vitro, and has a certain anti-tumor metastasis treatment effect.

The invention belongs to the technical field of new applications of medicines, and particularly relates to an aniline pyridine TEAD degradation agent, a preparation method thereof and an application of the degradation agent in preparation of antitumor drugs. According to the research, a novel aniline pyridine TEAD degradation agent with a clear structure is designed and synthesized by coupling a TEAD palmitoylation inhibitor niflumic acid serving as a lead compound with a CRBN type E3 ligase ligand through connecting chains with different lengths and different types by virtue of a computer-aided drug design means. The influence of the optimal compound (XY-3L) on cancer cell proliferation and cell functions is detected in an in-vitro cell experiment, and the curative effect of the optimal compound (XY-3L) in a melanoma lung metastasis model is explored in vivo.

The invention relates to a screening method of anti-breast cancer key targets of a traditional Chinese medicine composition for treating triple-negative breast cancer pulmonary metastasis, which sequentially comprises the following steps: component-target preliminary screening, two sample Mendel randomization, SMR and co-localization, full phenotype association and side effect evaluation, pathway enrichment, clinical expression verification, molecular docking verification and the like. After Mendel randomization (MR) and SMR are placed in network pharmacology, population genetic variation is used as a natural randomization tool, evidence of causal relationship between exposure (target level) and outcome (breast cancer risk) is provided on a public GWAS level, traditional association analysis mixing and reverse causal risk are reduced, and the false positive rate of network pharmacology prediction is greatly reduced; pheWAS-MR is introduced to perform system identification on phenotypes of various diseases, so that a potential off-target effect can be identified in advance, the multiple effects and possible adverse reactions of potential treatment targets in traditional Chinese medicine compound targets can be evaluated, powerful data support is provided for subsequent clinical test design and drug alert strategies, and the risk of later failure of research and development is effectively reduced.

The present application relates to the application of long-chain non-coding RNA HILAR inhibitor in the preparation of drugs for preventing or / and treating lung adenocarcinoma metastasis. The present application provides specific intervention means for HILAR, and verifies the effectiveness of inhibiting lung adenocarcinoma metastasis: after the expression of HILAR is targeted and silenced in vitro by small interfering RNA technology, the invasion ability of lung adenocarcinoma cells is significantly inhibited, and the metastasis phenotype is obviously reversed; more importantly, through the delivery of short hairpin RNA by adeno-associated virus vector, the formation and development of lung metastasis are effectively reduced in a lung adenocarcinoma metastasis mouse model, and the in vivo imaging shows that the tumor luminescence signal intensity of the experimental group is continuously lower than that of the control group, and the overall survival condition of the animal is improved.

The invention belongs to the technical field of drug delivery and tumor immunotherapy, and particularly relates to an oncolytic virus vesicle as well as a preparation method and application thereof. The preparation method comprises the following steps: co-incubating oncolytic adenovirus and platelets in a buffer system containing prostaglandin E2, and inducing to form an inner membrane encapsulation body; and activating and releasing the vesicles under the conditions of 36-38 DEG C and 4-6% CO2, and carrying out gradient centrifugal collection of 300g, 2000g, 10000g and 100000g. The particle size of the oncolytic virus-loaded vesicle is 50-200nm, the surface of the oncolytic virus-loaded vesicle contains CD41, CD61 and P-selectin, and the oncolytic virus-loaded vesicle can realize long circulation and lung targeting delivery of oncolytic viruses, is suitable for preparing drugs for treating breast cancer and breast cancer lung metastasis, and has a remarkable tumor inhibition effect.

The invention relates to the technical field of biological medicines, and particularly discloses a nanocapsule SMCPM and application thereof in medicines for treating or preventing osteosarcoma and pulmonary metastasis. The SMCPM is composed of a photosensitizer Ce6 carried by mesoporous silicon oxide-manganese oxide particles, an NRF2 inhibitor ML385 and an OS targeting peptide PT-7. Experiments prove that the SMCPM is high in penetrating power and strong in cell killing effect; by down-regulating NRF2 expression and reversing nuclear translocation, a biochemical inhibitory microenvironment can be effectively repaired, the tolerance of cells to active oxygen and epithelial-mesenchymal transition activated and induced by a NOTCH1 signal axis are remarkably reduced, the oxidative stress level of the cells is enhanced, and PIT-induced immunogenic cell death is promoted; the released Mn < 2 + > and double-stranded DNA can regulate and control an immunosuppressive microenvironment by activating an STING pathway in cells, thereby inhibiting the growth of osteosarcoma and preventing lung metastasis.

The invention belongs to the technical field of biological medicines, and provides application of combination of nicotinic acid and metformin in blocking the progress of esophageal squamous carcinoma. The invention discovers that nicotinic acid and metformin inhibit FRMD8 expression through different mechanisms for the first time so as to inhibit a JAK1-STAT3 signal channel. Nicotinic acid and metformin are combined to achieve a more remarkable inhibition effect on the ability of esophageal squamous cell carcinoma cells to subcutaneously grow in mice and generate pulmonary metastasis through caudal veins than a single drug, and a brand new drug direction is provided for prevention and treatment of esophageal squamous cell carcinoma.

The invention discloses an application of CD177 in treatment of lung metastasis of melanoma. The invention provides an application of CD177 as a target spot in screening of drugs for treating pulmonary metastasis of melanoma, an application of a CD177 inhibitor or a CD177 antibody in preparation of drugs for treating pulmonary metastasis of melanoma, and an application of a reagent for detecting CD177 in preparation of prognosis diagnosis tools for pulmonary metastasis of melanoma. Research finds that CD177 is highly expressed on neutrophil of a melanoma pulmonary metastasis focus, tumor infiltration of the neutrophil is remarkably inhibited by deletion of CD177, the progress of neutrophil-mediated mouse melanoma pulmonary metastasis is inhibited, and a CD177 monoclonal antibody can relieve the lung metastasis process of the melanoma. The invention provides a new target and a new treatment strategy for treatment of pulmonary metastasis of melanoma.

The invention discloses a hypoxia activating peptide-photosensitizer-drug conjugate and a preparation method and application thereof in the technical field of medicine, the conjugate takes indocyanine with a high molar extinction coefficient as a photosensitive core, distorted conjugate units are introduced to two sides of indole, the characteristic of'limited movement in molecules' is given to the conjugate, and radiation and non-radiation energy dissipation are balanced. Meanwhile, an azo bond sensitive to hypoxia is reasonably introduced between a light treatment module and a chemotherapy module to serve as a responsive linker, and is further coupled with two-molecule integrin targeting peptide cRGD, so that the azo bond is self-assembled into nanospheres in an aqueous solution, and a triple targeting mechanism, namely multivalent integrin receptor targeting, aggregation and tumor microenvironment hypoxia selective activation, is realized. In an in-situ osteosarcoma mouse model, the conjugate realizes real-time near-infrared two-region imaging, shows potent tumor inhibition, effectively inhibits lung metastasis, and does not detect obvious systemic toxicity.

The invention discloses a method for preventing lung relapse of cancer by using a cis-platinum lipid complex, and particularly discloses application of an inhalation type cis-platinum lipid complex (ILC) in preparation of a medicine for preventing or delaying osteosarcoma lung metastasis postoperative relapse or primary lung cancer postoperative relapse.

The invention discloses an application of a miR-1246 inhibitor in preparation of a medicine for preventing or treating postoperative metastasis of hepatocellular carcinoma (HCC). According to the application disclosed by the invention, the expression of miR-1246 in the serum exosome of an HCC patient after operation is obviously up-regulated, the expression of BMP9 protein is inhibited by directly targeting a GDF2 gene, and a downstream SMAD7-mediated metastasis inhibition signal channel is blocked, so that the HCC cell metastasis is driven, that is, the metastasis promoting process can be effectively reversed by inhibiting the function of miR-1246. In-vivo and in-vitro experiments prove that by using the miR-1246 inhibitor, the HCC cell anoikis apoptosis resistance, migration, invasion and in-vivo lung metastasis induced by the serum exosome after operation can be remarkably inhibited. The miR-1246 inhibitor can also be combined with a recombinant protein BMP9 to generate a synergistic anti-metastasis effect. Therefore, the miR-1246 inhibitor provides a new target and strategy for developing a novel anti-HCC postoperative metastasis drug.

The invention relates to an oligonucleotide lung targeting delivery system and application thereof in treatment of lung diseases, and relates to the technical field of biological medicines and nano-medicines. The invention designs a high-efficiency lung targeting oligonucleotide delivery drug, which comprises lipid nanoparticles, the lipid nanoparticles contain oligonucleotide and lipid components, and the lipid components are composed of 4-(N, N-dimethylamino) butyric acid (dilinoleyl) methyl ester, (2, 4-dimethylamino) butyric acid (dilinoleyl) methyl ester, (2, 4-dimethylamino) butyric acid (2, 4-dimethylamino) butyric acid (2, 4-dimethylamino) butyric acid (2, 4-dimethylamino) butyric acid (2, 4-dimethylamino) butyric acid The composition is composed of 1, 3-dioleoyl-propyl)-trimethylamine, dipalmitoyl phosphatidylcholine and pegylated lipid. A breakthrough of a nucleic acid medicine lung delivery technology is realized, in-vivo experiment verification results show that the lung aggregation efficiency is improved by about 2-4 times compared with that of traditional lipid nanoparticles, the lipid nanoparticles have remarkable lung metastatic tumor resisting activity, in-vivo experiments show that the lipid nanoparticles can inhibit growth of colorectal cancer lung metastatic tumors and prolong the survival time of mice, and the lipid nanoparticles have good application prospects. And the effect is better than that of 5-fluorouracil and regorafenib.

This invention belongs to the field of biomedical technology and discloses the application of olaparib in combination with taquimod in the preparation of anti-tumor metastasis drugs. This invention is the first to discover that olaparib and taquimod, even at low concentrations (i.e., concentrations that do not affect tumor cell proliferation), can effectively inhibit the invasion and metastasis of breast cancer cells, exhibiting high safety. Furthermore, when olaparib and taquimod are used in combination, the inhibitory effect on breast cell invasion and metastasis shows a synergistic enhancement trend, with significantly better efficacy than single-drug therapy, overcoming the limitations of monotherapy. Moreover, the combination of olaparib and taquimod can effectively inhibit lung metastasis of breast cancer, providing a new theoretical basis and medication regimen for anti-metastasis treatment of breast cancer.

The application discloses a culture medium for constructing a liver cancer lung metastasis microtumor model and application thereof. The application relates to the technical field of biology, and provides a culture medium for constructing a liver cancer lung metastasis microtumor model, which is composed of three antibacterial and antifungal agents, HEPES, GlutaMax, human recombinant proteins EGF, HGF, IL-2, IL-15, R-spondin1, CXCL12, recombinant human lung surfactant proteins SP-A, SP-D, forskolin, A83-01, N-acetyl-L-cysteine, nicotinamide, N2 additives, B27 and a basic culture medium. The culture success rate of the liver cancer lung metastasis microtumor model is effectively improved.

The application provides application of idebenone in preparation of a medicine for treating osteosarcoma. The application of idebenone or a pharmaceutically acceptable salt thereof in preparation of the medicine for treating osteosarcoma is achieved by carrying out proliferation experiments (CCK8 method) and invasion experiments (transwell invasion experiment) of osteosarcoma cell lines in vitro, quantitative analysis of cell viability in the CCK8 method proliferation experiment and quantitative analysis of the number of penetrated cells in the transwell invasion experiment; and constructing a nude mouse CDX (cell-derived xenograft) model, a PDX (human-derived xenograft) model and a tibial orthotopic / metastatic tumor model, intraperitoneally injecting idebenone, and quantitatively analyzing the tumor volume and tumor weight in the CDX model, the tumor volume and tumor weight in the PDX model and the tumor volume, the weight of the affected limb and the number of lung metastases in the tibial orthotopic / metastatic tumor model, which fully indicates that idebenone can inhibit the proliferation, invasion and metastasis of osteosarcoma.

The application discloses a flaxseed oil body carrier for treating hepatocellular carcinoma by inducing immunogenic cell death and a preparation method and application thereof. The flaxseed oil body is obtained by a water extraction method, then curcumin is loaded on the flaxseed oil body, and then mineralization is performed to obtain the flaxseed oil body carrier for treating hepatocellular carcinoma by inducing immunogenic cell death. Through in vitro and in vivo experiments, it is proved that the carrier can effectively inhibit the growth of hepatocellular carcinoma, and the characterization results show that the carrier can further enhance the tumor killing effect by activating the immune system. Further, after the anti-PD-L1 is combined with the carrier, a synergistic effect can be produced, the treatment effect of the alpha PD-L1 immunotherapy on the anti-HCC lung metastasis is enhanced, and it is proved that the carrier can be used for combining the alpha PD-L1 immunotherapy to enhance the anti-tumor effect, and has a wide application prospect.

The application discloses application of ginsenoside Rc and derivatives or salts thereof in preparation of a medicine for preventing and / or treating early lung metastasis of Lewis lung cancer and / or combination with other tumors. The ginsenoside Rc of the application shows better prevention and treatment effects on early lung metastasis of Lewis lung cancer and higher safety than cisplatin in a tumor-bearing mouse model, and no adverse reactions are found.

This invention belongs to the field of biomedical technology, specifically relating to the application of erythrocyte-derived exosomes in the preparation of drugs for melanoma lung metastasis. This invention discovers that treatment with erythrocyte-derived exosomes can inhibit the metastatic ability of malignant melanoma, thus proposing the application of erythrocyte-derived exosomes in the preparation of drugs for melanoma lung metastasis.

This invention provides a nucleic acid aptamer that targets and binds to the IGF2BP2 protein and its application, belonging to the field of pharmaceutical technology. This invention is the first to design a highly specific nucleic acid aptamer targeting the RNA recognition protein IGF2BP2, obtaining a nucleic acid aptamer that can target and specifically bind to the IGF2BP2 protein (see SEQ ID No. 1-2). This nucleic acid aptamer can effectively inhibit the activity of tumor cells, tumor stem cells, and breast cancer brain metastases, breast cancer lung metastases, breast cancer liver metastases, breast cancer kidney metastases, and breast cancer bone metastases, providing a new drug component for the treatment of malignant and refractory tumors (especially glioblastoma and distant metastatic breast cancer). Furthermore, it was discovered that modification with N6-methyldeoxyadenosine monophosphate can further enhance the specificity of the nucleic acid aptamer and strengthen its efficacy in inhibiting tumor cell activity.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a GABRD gene expression inhibitor in preparation of a medicine for inhibiting lung metastasis of liver cancer cells. The GABRD gene expression inhibitor is a CRISPR-Cas9 tool for targeted knockout or knockdown of a GABRD gene and a related biological reagent, and a sense strand sequence of sgRNA of the CRISPR-Cas9 tool is as shown in SEQ ID NO: 1. Experiments prove that lung metastasis of liver cancer cells can be remarkably inhibited by inhibiting expression of the GABRD gene.

The application provides a slightly acid response type biomimetic nanovesicle and a preparation method and application thereof. The outer layer of the slightly acid response type biomimetic nanovesicle is composed of a PD-1 biological cell membrane, and apatinib is loaded into the slightly acid response type PEG-PAEs nanoparticle hydrophobic inner core. Apa-PPNP@mPD-1, as a new dosage form of combined administration of a small molecule inhibitor and a large molecule inhibitor, can precisely co-deliver apatinib and PD-1 protein to tumor tissues, release the drug in response to the slightly acid environment of the tumor, has a significant treatment effect of tumor growth regression and effective inhibition of lung metastasis, and also avoids toxic side effects on normal tissues, and has good biocompatibility.

This invention discloses the application of the CYYR1 gene in the preparation of drugs for treating YAP-highly activated tumors, belonging to the field of biotechnology. This invention provides the application of the CYYR1 gene in the preparation of drugs for treating YAP-highly activated tumors, wherein the drugs are capable of promoting CYYR1 gene overexpression. Experiments have shown that overexpression of CYYR1 can significantly inhibit the proliferation, invasion, and colony formation of YAP-highly activated breast cancer cells MDA-MB-231, and inhibit tumorigenesis and lung metastasis in nude mice. Therefore, the CYYR1 gene can be used as a drug, drug target, or target gene in gene therapy for the treatment of YAP-highly activated tumors. This invention provides new diagnostic and therapeutic ideas and methods for the treatment of YAP-highly activated tumors.

This invention belongs to the field of biomedical technology and discloses the application of exosomal lncOSLMT in the diagnosis and treatment of osteosarcoma lung metastases. This invention discloses the application of reagents for detecting lncOSLMT in the preparation of products for risk diagnosis or prognostic assessment of osteosarcoma lung metastases. Through research, this invention found that lncOSLMT selectively accumulates in exosomes released by osteosarcoma cells with high metastatic potential. Its elevated expression is positively correlated with the incidence of lung metastasis and serves as an independent prognostic factor for poor prognosis in osteosarcoma patients. This invention elucidates the regulatory role of lncOSLMT in the pre-metastatic microenvironment of osteosarcoma lung metastases and its effect on lung metastasis, clarifying that targeting lncOSLMT has significant clinical translational value for targeted treatment of osteosarcoma lung metastases, especially in osteosarcoma liquid biopsy and early metastasis prediction, and is of great importance in ensuring adequate clinical safety.

This invention relates to the field of animal model construction, specifically a method for constructing a lung metastasis model of the human melanoma A375-M1 cell line. The human melanoma A375-M1 cell line lung metastasis model was constructed using tail vein injection, and in vivo identification was performed using PET-CT and MRI, while in vitro identification was performed using Bouin's and H&E assays. The human melanoma lung metastasis model constructed by this invention has the advantages of short construction time, simple method, and 100% modeling success rate. This metastasis model simulates the development process and pathological characteristics of melanoma lung metastasis, solving the problem of the lack of ideal animal models for human melanoma lung metastasis. It contributes to the exploration and screening of anti-lung metastasis drugs for human melanoma and plays a positive role in promoting new strategies for combating melanoma lung metastasis.